Approach to the treatment-naïve patient with HCV genotype 1 infection.

Journal Article (Journal Article;Review)

In May 2011, the protease inhibitors boceprevir and telaprevir were approved in combination with peginterferon-α and ribavirin for the treatment of genotype 1 chronic hepatitis C virus infection in the United States. These regimens brought substantial improvements in sustained virologic response rates, especially for treatment-naïve patients. This article reviews the approach to therapy with these genotype 1 treatment-naïve patients.

Full Text

Duke Authors

Cited Authors

  • Muir, AJ

Published Date

  • December 2012

Published In

Volume / Issue

  • 26 / 4

Start / End Page

  • 893 - 901

PubMed ID

  • 23083822

Electronic International Standard Serial Number (EISSN)

  • 1557-9824

Digital Object Identifier (DOI)

  • 10.1016/j.idc.2012.08.012


  • eng

Conference Location

  • United States